Carbonic anhydrase inhibitors protect against tau protein build-up
Nov 1, 2024 · Scientists at the UK Dementia Research Institute, University of Cambridge, have identified a drug commonly used to treat glaucoma can protect against tau protein build-up in …
New insights into adhesion GPCRs spark drug design potential
Dec 27, 2024 · Researchers at the University of Chicago have uncovered the full structure of adhesion GPCRs, revealing new activation mechanisms.
Immuno-oncology innovations redefining cancer treatment in 2024
Jan 23, 2024 · What innovative approaches and technologies are anticipated to reshape immuno-oncology treatments in 2024? Immuno-oncology, notably through checkpoint inhibitors, has …
Drug Target Review: Leading Research & Insights in Drug Discovery
Featured FDA’s Project Optimus: A new era in oncology drug dosing Explore how FDA’s Project Optimus is reshaping oncology drug dosing strategies, with insights on precision medicine, …
New AI model may enable more targeted prostate cancer treatment
Oct 30, 2024 · Based on MRI scans from 732 prostate cancer patients, the AI model identified the edges of 85 percent of the most radiologically aggressive lesions.
The art and science of drug formulation - Drug Target Review
Aug 9, 2024 · Drug formulation is a cornerstone of modern medicine, turning raw active ingredients into consumable, effective therapies. This critical phase in drug development …
Exploring the potential of ADCs beyond oncology - Drug Target …
Aug 6, 2024 · What are the main therapeutic areas beyond oncology where ADCs show potential? A number of areas represent significant opportunities for Antibody Drug Conjugates (ADCs) …
NKTR-255 shows positive results in lymphoma therapy
Dec 16, 2024 · Nektar Therapeutics presented promising results at the 66th Annual ASH Meeting, showing that NKTR-255, an investigational IL-15 agonist, significantly boosts the complete …
Novel nasal spray effectively prevents influenza infection
Sep 25, 2024 · The nasal spray reduced influenza virus levels by >99.99 percent, which could safeguard public health if validated in humans.
Tessera Therapeutics: addressing Alpha-1 Antitrypsin Deficiency
Jun 18, 2024 · At this year’s ASGCT conference, Tessera shared progress on its RNA Gene Writers™, including promising data in preclinical models of AATD.